Using this technology, it is also possible to adapt the vaccine to modified virus mutations within a short space of time. Thanks to the platform technology used, mRNA vaccines are easier to manufacture and guarantee the production of several million doses in only a few weeks. Persons who still become ill despite vaccination can expect to have a relatively mild disease progression. To what extent boosters are necessary, as is the case with the influenza vaccine for example, is still unclear and will continue to be the subject of clinical trials. However, owing to the residual risk, distancing and hygiene rules will continue to apply to vaccinated persons as well. Further studies are required to show how long the protection afforded by the vaccine lasts. The Robert Koch Institute assumes that, from the fifteenth day after the last vaccine dose, fully vaccinated persons have a lower risk of transmitting the coronavirus than persons with a negative test result. The Comirnaty® vaccine by BioNTech/Pfizer is highly effective against the coronavirus. In vaccinated persons, the probability of getting COVID-19 after being infected falls by around 95 percent. The risk of transmission is also significantly reduced. This then also concludes the body’s own production of spike proteins. The mRNA contained in the vaccine, on the other hand, is broken down in the body within a matter of days. If a “real” coronavirus enters the body in the wake of a subsequent SARS-CoV-2 infection, the immune system immediately recognises it due to its spike proteins and can quickly and effectively fight it. The latter recognises the protein as a foreign body and develops antibodies and defence cells to fight it, thus generating a protective immune response. The body’s cells produce the protein themselves with the aid of the blueprint and present it to the immune system. When a person is vaccinated with Comirnaty® by BioNTech/Pfizer, the spike protein blueprint enters the human muscle inside a protective coating composed of tiny fat droplets known as lipids. It is with this distinctive protein – we know it from the depictions of the virus as the spike on the virus’ surface – that the coronavirus penetrates human cells. The protein itself is perfectly harmless.
Once thawed, do not refreeze.Īs with the COVID-19 vaccine by Moderna, the Comirnaty® vaccine by BioNTech/Pfizer is a so-called mRNA vaccine. The “m” in this new vaccine technology's name stands for “messenger” and RNA for ribonucleic acid, a chemical compound found in body cells. The mRNA provides the blueprint for a small component of the coronavirus, specifically its spike protein. 30☌), it can be kept (undiluted) for a maximum of two hours. Undiluted, the vaccine can keep for a maximum of 31 days including the time for thawing and transport, if stored in a refrigerator at between 2☌ and 8☌. Storage: Storage at -90 ☌ to -60 ☌: up to six months.Vaccination schedule: Two doses 6 weeks apart.Administration: By injection into the muscle of the upper arm (intramuscular).Typical vaccine reactions: Headaches, pain in the limbs and joints, pain and/or redness at the injection site, fatigue or flu-like symptoms, nausea.The vaccine is also recommended for children and young people between the ages of 12 and 15 with specific pre-existing conditions as they are at a higher risk of severe COVID-19 infections. Vaccination recommendation: Based on the currently available data, the Standing Committee on Vaccination (STIKO) recommends the Comirnaty® vaccine for all citizens from the age of 16.Efficacy: If the interval of six weeks between the two shots is observed, as recommended by the Standing Committee on Vaccination (STIKO), Comirnaty® provides an efficacy of up to 95 percent among vaccinated persons of all age groups.Vaccine type + mode of action: An mRNA vaccine that introduces a blueprint for a feature of the SARS-CoV-2 virus (the spike protein) into the cells, enabling the body to produce the antibody itself so that the immune system is able to trigger a corresponding immune response.Authorisation holder: The German biotechnology firm BioNTech and the American pharmaceutical corporation Pfizer.
0 kommentar(er)
